Soligenix, Inc. (OTC standard Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced the declaration of an article online in Vaccine. The article describes the
studious identification of neutralizing and non-neutralizing B-cell epitopes on ricin toxin's enzymatic A subunit (RTA). An inactivated form of RTA is the primary constituent of RiVax™, the Company's proprietary vaccine against ricin toxin. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy...

More: - The rest...